Latest filings (excl ownership)
15-12G
Securities registration termination
6 Feb 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
EFFECT
Notice of effectiveness
31 Jan 23
RW
Registration withdrawal request
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
POS AM
Prospectus update (post-effective amendment)
26 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 23
25-NSE
Exchange delisting
25 Jan 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Jan 23
8-K
Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
17 Jan 23
8-K
Viveve Announces Completion of Pivotal U.S. PURSUIT Trial
15 Dec 22
S-1/A
IPO registration (amended)
6 Dec 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Dec 22
8-K
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
1 Dec 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Nov 22
S-1
IPO registration
10 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
10 Nov 22
D
$14.68 k in equity, sold $14.68 k, 1 investor
26 Oct 22
8-K
Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
4 Oct 22
EFFECT
Notice of effectiveness
29 Sep 22
Latest ownership filings
4
Steven L Basta
5 Jan 23
4
Scott Durbin
5 Jan 23
4
DEBORA JORN
5 Jan 23
4
Arlene Morris
5 Jan 23
4
Sharon Collins Presnell
5 Jan 23
4
Jim B Robbins
5 Jan 23
SC 13G/A
Hudson Bay Capital Management LP
4 Feb 22
SC 13G/A
Empery Asset Management, LP
18 Jan 22
4
DEBORA JORN
6 Jan 22
4
Arlene Morris
6 Jan 22
4
Sharon Collins Presnell
6 Jan 22
4
Jim B Robbins
6 Jan 22
4
Steven L Basta
6 Jan 22
4
Scott Durbin
6 Jan 22
4
Steven L Basta
17 Dec 21
4
Scott Durbin
17 Dec 21
4
Jim B Robbins
17 Dec 21
4
Steven L Basta
25 Jun 21
4
Scott Durbin
25 Jun 21
4
Arlene Morris
25 Jun 21
4
DEBORA JORN
25 Jun 21
4
Sharon Collins Presnell
25 Jun 21
4
Jim B Robbins
25 Jun 21
SC 13G/A
Alyeska Investment Group, L.P.
16 Feb 21
SC 13G/A
Hudson Bay Capital Management LP
11 Feb 21
4
Scott Durbin
22 Jan 21
4
DEBORA JORN
22 Jan 21
4
Arlene Morris
22 Jan 21
4
Sharon Collins Presnell
22 Jan 21
4
Jim B Robbins
22 Jan 21
4
Steven L Basta
22 Jan 21
SC 13G
Empery Asset Management, LP
19 Jan 21
SC 13G
Lincoln Park Capital Fund, LLC
19 Jan 21
4
Sharon Collins Presnell
30 Oct 20
3
Sharon Collins Presnell
30 Oct 20
4
Arlene Morris
22 Sep 20
4
Steven L Basta
22 Sep 20
4
DEBORA JORN
22 Sep 20
4/A
Change in insider ownership (amended)
18 Feb 20
4/A
Change in insider ownership (amended)
18 Feb 20